Aytu BioPharma

141 articles about Aytu BioPharma

• Aytu BioScience Announces Study Initiation And First Patient Dosing In Prostate Cancer Clinical Study With Hybridyne Imaging Technologies For Prostascint In Combination with Hybridyne's ProxiScan Transrectal Camera

  6/6/2016

• BIO2016: Aytu BioScience To Attend The 2016 Biotechnology Innovation Organization International Convention

  5/31/2016

• Aytu BioScience To Optimize Capitalization In Support Of Future Anticipated Uplisting Of Its Common Stock To A National Exchange

  5/25/2016

• Aytu BioScience To Present At 2016 Marcum MicroCap Conference

  5/24/2016

• Aytu BioScience Initiates Commercial Expansion To Support July 2016 Launch Of Natesto

  5/18/2016

• Aytu BioScience Provides Third Fiscal Quarter 2016 Business Update

  5/11/2016

• Aytu BioScience Demonstrates Expanded Clinical Utility Of MiOXSYS For Assessing Oxidative Stress As A Marker For Male Infertility With New Study

  5/10/2016

• Aytu BioScience Announces Closing Of Public Offering

  5/6/2016

• Aytu BioScience To Provide Its Third Fiscal Quarter Business Update

  5/5/2016

• Aytu BioScience Announces Pricing Of $7.5 Million Public Offering Of Common Stock And Warrants

  5/3/2016

• Aytu BioScience Enters $2 Billion Testosterone Replacement Market With Acquisition Of U.S. Commercial Rights To Natesto

  4/25/2016

• Aytu BioScience Strengthens Board With Appointment Of First Independent Director

  4/13/2016

• Aytu BioScience Demonstrates Clinical Utility of MiOXSYS For Measuring Oxidative Stress Levels In Semen As A Marker For Male Infertility At American Society Of Andrology 41st Annual Meeting In New Orleans, LA

  4/5/2016

• Aytu BioScience Awarded Health Canada Approval For Its Mioxsys System For Male Infertility

  3/31/2016

• Aytu BioScience Announces U.S. Co-Promotion Agreement For Primsol

  3/29/2016

• Aytu BioScience Announces Study Collaboration With Hybridyne Imaging Technologies, Inc. For Minimally Invasive Prostate Cancer Detection

  3/1/2016

• Aytu BioScience Provides Second Fiscal Quarter Business Update

  2/17/2016

• Aytu BioScience To Provide Its Second Fiscal Quarter Business Update

  2/11/2016

• Aytu BioScience Announces First Commercial Sales For Company's MiOXSYS System For Male Infertility

  2/9/2016

• Aytu BioScience To Present At 2016 Disruptive Growth & Healthcare Conference

  2/3/2016